Monograph
J07BH02 - Rota Virus, Pentavalent, Live, Reassorted |
Propably not porphyrinogenic |
PNP |
Side effects
Fever, diarrhea and vomiting are reported as very common side effects.
Rationale
Based on the pharmacokinetics of the rotavirus vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Live human-bovine rotavirus reassortants.
Therapeutic characteristics
The rotavirus vaccine is indicated for the active immunization of infants from the age of 6 weeks to 32 weeks for prevention of gastroenteritis due to rotavirus infection. It is administered orally by a 3-dose regimen given with intervals of at least 4 weeks. The first dose may be given from the age of 6 weeks and no later than 12 weeks. The third (last) dose may be given up to the age of 32 weeks, but preferably before the age of 20-22 weeks.
Metabolism and pharmacokinetics
The rotavirus vaccine is not metabolized by the cytochrome P450 system.
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | European Public Assessment Report, RotaTeq (SPC).European Medicines Agency (EMA).
|
|
| 2. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024